Cytokine Signalling Forum

Professor Roy Fleischmann, Clinical Professor of Medicine at the University of Texas Southwestern Medical Centre. In this addition Professor Fleischmann discusses his recent paper 'Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.'

Dr Claudia Salinas, Director Pharmacoepidemiology at Eli Lilly and Company, Indianapolis, USA. In this addition Dr Salinas discusses her recent paper 'Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease registries and Claims Databases.'

Join Prof Iain McInnes as he reviews two interesting papers. The first highlights one of the three systematic literature reviews carried out to inform the 2022 EULAR RA management recommendations task force with the available evidence published since 2019. The second paper in today’s podcast looks at the recommendations themselves, by Smolen, et al, and I’ll highlight what’s remained the same and what’s changed from the 2019 recommendations. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professor Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications details the 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis. The second of today’s papers explores the efficacy and safety of bDMARDs in axSpA managment. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Prof Iain McInnes as he reviews two interesting papers. The first paper aimed to compare the risk of MACEs and VTEs for patients initiating a JAKinib (tofacitinib and baricitinib) and those initiating adalimumab (TNFi) among a large and comprehensive real-world population of patients with RA. Our second paper aimed to evaluate the efficacy and safety of FIL200 and FIL100 compared with placebo and ADA, all with background MTX, in patients with MTX-IR RA in subgroups of those with all four PPFs versus those with fewer than four PPFs. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professor Iain McInnes and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in October 2022. Our first paper seeks to examine the efficacy and safety of ixekizumab in patients with PsA and PsO. Our second paper today will highlight the comparative efficacy of multiple treatments in PsA utilising new data within an NMA framework. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Discussing Rheumatology: October 2022 by The CSF

Join Professors Iain McInnes and Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the feild of axSpA theraputics, providing their own insights and experience into two very interesting publications. The first of our publications reports the efficacy and safety results for patients treated with ixekizumab for up to 116 weeks. The second of today’s papers evaluated the effectiveness and safety profile of COMBIO, or Combination of Targeted Therapies, in clinical settings. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Prof Iain McInnes as he reviews two interesting papers. The first covers the impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis. The second discusses infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dr Eduardo Mysler, from the School of Medicine, University of Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Mysler discusses his recent paper 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'

Join Professors Iain McInnes and Phillip Mease as well as Doctors Frank Behrens and Laura Coates as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in August 2022. Our first paper aims to highlight the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients by looking at a single tender point out of the six-point LEI. The second of today’s papers evaluates the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial. Finally, our third paper reports the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dr Ameen Jubber, specialist registrar in rheumatology at the University Hospitals of Leicester NHS Trust, in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Jubber discusses his recent editorial paper reviewing the evidence for VTE risk in JAKinibs, and whether this risk also extends to the second-generation JAKinibs.

Join Prof Iain McInnes as he reviews two interesting papers. The first covers new data from China on the first-in-human trial of KL130008. The second reports on the exposure-response analyses of filgotinib for dose confirmation. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Dr Kim Lauper, from the Division of Rheumatology, Department of Internal Medicine and Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneve, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Lauper discusses her latest paper; Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration.

Join Prof. Baraliakos and Dr Mehta as they discuss the latest top research in axSpA. In this edition, our Steering Committee members look at three key papers published in July 2022. Our first paper investigated upadacitinib efficacy and safety in axSpA. The second of today’s looks at factors associated with drug-free remission in early onset axSpA patients. Finally, our third paper focuses on the association of bDMARD treatments with hospital acquired infections. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Prof Iain McInnes as he reviews two interesting papers from May and June. The first -by Faquetti , et al.- provides some insightful information into the pharmacological effects of tofacitinib and baricitinib. Our second paper then goes on to evaluate the real-life effectiveness and safety outcomes of four current second-line therapies of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professors McInnes and Nash as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in May 2022. Our first paper highlights investigations of imaging characteristics and clinically assess heel enthesitis in SpA. The second of today’s paper evaluates the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab. Finally, our third paper reports the efficacy and safety of deucravacitinib in patients with active PsA. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Author Interview: Diego Kyburz by The CSF

Discussing Rheumatology: June 2022 by The CSF

Discussing axSpA: Episode 1 by The CSF